Chantix Varenicline Tablets Recalled for Nitroso Impurity
Pfizer is recalling Chantix (varenicline) tablets nationwide due to the presence of N-nitroso-varenicline impurity above FDA's acceptable interim intake limit, a manufacturing deviation.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is an FDA Class II classification with a manufacturing deviation (CGMP non-compliance) involving an impurity above acceptable limits. No illnesses or injuries have been reported in the source text, making this a precautionary recall typical of moderate severity.
Plain-English summary
Pfizer Inc. is recalling Chantix (varenicline) tablets 0.5 mg/1 mg, 56-tablet packages (NDC 00069-0471-03) distributed nationwide. The product is made in Ireland and distributed by Pfizer Labs.
The recall was initiated because certain lots contain the N-nitroso-varenicline impurity at levels exceeding FDA's acceptable interim intake limit. This is a current good manufacturing practices (CGMP) deviation.
The affected lots are: 00018522, 00018523, 00018739, 00018740, 00020231, 00020232, 00020357, 00020358, 00020716, 00020813, 00021288, 00021289, 00021420, 00021687, 00021688, 00021788, 00021789, 00021790, 00021791, 00021792, 00022819, 00022851, 00023136, 00023137, 00023190, 00023448, DM0275, DM0276, DM0277, DY4470, EC5911, EC5912, ED6814, ET1600, ET1603, ET1607, ET1609, ET1611, with expiration dates between August 2021 and January 2023.
Patients taking affected doses should consult their healthcare provider about whether to continue use or switch to an alternative product. Do not discontinue smoking cessation treatment without medical guidance.
The recalled product
- Product
- Chantix (varenicline) tablets 0.5mg/1mg, 56 Tablets, Rx only, Distributed by Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Ireland, NDC 00069-0471-03. carton containing one blister pack of 11 0.5 mg tablets and one blister pack containing 42.1 mg tablets.
- Manufacturer
- Pfizer Inc.
- Category
- Drug — Oral tablet
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lots 00018522
- 00018523
- 00018739
- 00018740
- 00020231
- 00020232
- 00020357
- 00020358
- 00020716
- 00020813
- 00021288
- 00021289
- 00021420
- 00021687
- 00021688
- 00021788
- 00021789
- 00021790
- 00021791
- 00021792
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 4 recalled by Pfizer Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same manufacturer · Pfizer Inc.
See all →- HighSodium bicarbonate injection vials recalled for lack of assurance of sterility
FDA (Drugs) · 2025-08-27
- HighEpinephrine injection vials recalled for lack of assurance of sterility
FDA (Drugs) · 2025-08-27
- HighBicillin L-A 2.4 million unit vials recalled after particulates found
FDA (Drugs) · 2025-08-06
- HighBicillin L-A penicillin vials recalled after particulates found during visual inspection
FDA (Drugs) · 2025-08-06
- ModerateDobutamine Injection Recall Due to Discoloration and Cracked Vials
FDA (Drugs) · 2025-07-02
Same hazard · impurity nitroso compound
See all →- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27